Monitor for regulatory submission updates and potential Phase 3 data from the ongoing PHOENYCS program (NCT06617325). DZP's steroid-sparing profile could differentiate it in the SLE market if approved, but near-term stock impact is limited given no approval or revenue guidance.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $195.82entry
- T+1 · 6mo ago −0.27%α +2.33% · $195.30
- T+5 · 5mo ago +2.12%α +4.67% · $199.96
- T+20 · 4mo ago +10.37%α +11.99% · $216.12
- T+60 · 3mo ago +11.24%α +9.62% · $217.83
Price Chart
How similar events traded
Executive Summary
Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE), showing patients achieved sustained disease control with lower glucocorticoid doses through Week 48 versus placebo. The data support DZP's potential to reduce steroid exposure and flare rates, but DZP remains investigational with no regulatory approval.
Key Facts
- Phase 3 PHOENYCS GO data presented at EULAR 2026: DZP plus standard of care showed sustained disease control at lower glucocorticoid doses through Week 48 vs placebo.
- Post hoc analysis: patients with baseline glucocorticoid dose >7.5 mg/day prednisone equivalent on DZP were more likely to achieve disease control while tapering to ≤7.5 mg/day.
- DZP demonstrated a generally favorable safety profile; serious treatment-emergent adverse events were less frequent in the DZP arm vs placebo.
- DZP is an investigational biologic (CD40L inhibitor) in Phase 3 development for SLE under a UCB/Biogen collaboration; not approved by any health authority.
- Phase 3 PHOENYCS GO study was recently published in The Lancet (May 29, 2026).
Financial Impact
No financial figures provided; DZP is pre-commercial with no revenue or cost data disclosed.
Risk Factors
- DZP is not approved by any regulatory authority; clinical development may fail or be delayed.
- Competition from approved SLE therapies (e.g., belimumab, anifrolumab) could limit commercial potential.
- Safety profile requires further characterization; treatment-emergent adverse events were more common with DZP vs placebo.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306500 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $253.40 −0.00% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $253.40 +0.06% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $253.40 −0.58% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $253.40 +3.83% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $253.40 +3.83% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $253.40 +8.53% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $253.40 +10.46% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $253.40 +15.24% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $253.40 +17.59% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $253.40 +14.75% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers